Coverage
Filings
| Filing | Date |
|---|---|
| ORION CORPORATION SHARE REPURCHASE 03.01 | 3 Jan 2003 |
| ORION CORPORATION SHARE REPURCHASE 02.01 | 2 Jan 2003 |
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).